- Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab(2018)
Auteurs: Tom van Cann, Patrick Schöffski, Paul Clement, Oliver Bechter, Isabel Spriet, Constantinus Politis, Joseph Schoenaers, Herlinde Dumez, Patrick Neven, Kristiaan Nackaerts, et al.
Pagina's: 100 - 109
- Incidence of medication-related osteonecrosis of the jaw in patients treated with both bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors(2018)
Auteurs: Tom van Cann, Annelies Verbiest, Paul Clement, Oliver Bechter, Ludo Willems, Isabel Spriet, Constantinus Politis, Joseph Schoenaers, Herlinde Dumez, Patrick Neven, et al.
Pagina's: 869 - 878
- Activity and safety of crizotinib in patients with advanced clear cell sarcoma with MET alterations. European Organization for Research and Treatment of Cancer phase 2 trial 90101 "CREATE"(2017)
Auteurs: Patrick Schöffski, Agnieszka Wozniak, Raf Sciot, Maria Debiec-Rychter, Tom van Cann
Pagina's: 3000 - 3008
- Treatment options for anthracycline-resistant, advanced soft-tissue sarcoma: the role of eribulin(2017)
Auteurs: Patrick Schöffski, Tom van Cann, Jasmien Cornillie
Pagina's: 445 - 453
- Single-Center Experience with Intimal Sarcoma, an Ultra-Orphan, Commonly Fatal Mesenchymal Malignancy(2017)
Auteurs: Raf Sciot, Marion Delcroix, Maria Debiec-Rychter, Barbara Dewaele, Jasmien Cornillie, Tom van Cann, Bart Meyns, Patrick Schöffski
Pagina's: 353 - 359
- Biology and management of clear cell sarcoma: state of the art and future perspectives(2016)
Auteurs: Jasmien Cornillie, Tom van Cann, Agnieszka Wozniak, Daphne Hompes, Patrick Schöffski
Pagina's: 839 - 845